Amphastar Pharmaceuticals, Inc. (AMPH)
28.13
+0.02
(+0.07%)
USD |
NASDAQ |
Nov 20, 10:20
Amphastar Pharmaceuticals Cash from Operations (Quarterly) : 43.30M for Sept. 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 43.30M |
| June 30, 2026 | 51.32M |
| March 31, 2026 | 47.84M |
| December 31, 2025 | 32.86M |
| September 30, 2025 | 52.58M |
| June 30, 2025 | 35.59M |
| March 31, 2025 | 35.08M |
| December 31, 2024 | 29.02M |
| September 30, 2024 | 59.96M |
| June 30, 2024 | 69.11M |
| March 31, 2024 | 55.29M |
| December 31, 2023 | 23.86M |
| September 30, 2023 | 64.33M |
| June 30, 2023 | 54.92M |
| March 31, 2023 | 40.38M |
| December 31, 2022 | 15.22M |
| September 30, 2022 | 20.06M |
| June 30, 2022 | 2.726M |
| March 31, 2022 | 50.76M |
| December 31, 2021 | 40.44M |
| September 30, 2021 | 2.569M |
| June 30, 2021 | 32.16M |
| March 31, 2021 | 22.82M |
| December 31, 2020 | 16.89M |
| September 30, 2020 | 8.807M |
| Date | Value |
|---|---|
| June 30, 2020 | 30.09M |
| March 31, 2020 | 1.477M |
| December 31, 2019 | 5.652M |
| September 30, 2019 | -12.00M |
| June 30, 2019 | 51.72M |
| March 31, 2019 | -3.61M |
| December 31, 2018 | 9.517M |
| September 30, 2018 | 15.78M |
| June 30, 2018 | 4.533M |
| March 31, 2018 | 8.36M |
| December 31, 2017 | 9.765M |
| September 30, 2017 | 2.472M |
| June 30, 2017 | 4.574M |
| March 31, 2017 | 22.40M |
| December 31, 2016 | 14.01M |
| September 30, 2016 | 1.298M |
| June 30, 2016 | 9.326M |
| March 31, 2016 | 13.93M |
| December 31, 2015 | 3.287M |
| September 30, 2015 | 3.553M |
| June 30, 2015 | 2.503M |
| March 31, 2015 | 1.338M |
| December 31, 2014 | 12.32M |
| September 30, 2014 | 13.63M |
| June 30, 2014 | 0.934M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Viatris, Inc. | 899.40M |
| Johnson & Johnson | 7.72B |
| Eli Lilly & Co. | 11.40B |
| Merck & Co., Inc. | 6.558B |
| Pfizer Inc. | 5.375B |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -63.96M |
| Cash from Financing (Quarterly) | 1.71M |
| Free Cash Flow | 44.52M |
| Free Cash Flow Per Share (Quarterly) | -1.410 |
| Free Cash Flow to Equity (Quarterly) | -64.51M |
| Free Cash Flow to Firm (Quarterly) | -55.94M |
| Free Cash Flow Yield | 3.71% |